LGR5 and neoplasm: In the previous study, we found that knocking down the Arf1 pathway in mouse CSCs with Lgr5‐CreER and Axin2‐CreER activated a systemic anti‐tumor immune response to destroy tumors.[2] To demonstrate that the antitumor activity of DU101 and DU102 specifically relies on immune response, we first treated nude mice with allograft tumors from CT26 cells and found that DU101 or DU102 treatment did not affect tumor weights (Figure S6a–d, Supporting Information).